溢多利(300381) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥397,419,671.58, a decrease of 1.27% compared to ¥402,535,465.00 in the same period last year[7] - Net profit attributable to shareholders increased by 35.38% to ¥25,379,143.78 from ¥18,746,963.62 year-on-year[7] - The net profit after deducting non-recurring gains and losses rose by 79.01% to ¥23,429,235.81 compared to ¥13,088,046.01 in the previous year[7] - Basic earnings per share increased by 21.60% to ¥0.0518 from ¥0.0426 year-on-year[7] - Net profit increased by 18,014,986.26 CNY, a growth of 106.46%, driven by significant sales revenue growth of biological enzyme products and functional feed additives[17] - Net profit for Q1 2021 was CNY 34,856,133.57, compared to CNY 16,921,427.93 in the same period last year, representing a significant increase[46] - The total comprehensive income for the period was CNY 22,725,639.17, compared to CNY 14,838,681.35 in the same period last year, reflecting a growth of 53.3%[51] Cash Flow - The net cash flow from operating activities surged by 107.54% to ¥60,953,891.69 from ¥29,369,882.06 in the same period last year[7] - Operating cash flow net amount was 60,953,891.69 CNY, a year-on-year increase of 107.54%, attributed to increased cash received from sales[18] - Total cash inflow from operating activities was CNY 423,530,749.89, compared to CNY 361,067,109.34 in the prior year, representing an increase of 17.3%[54] - The company reported a cash outflow from investing activities of CNY 79,505,785.00, which is an increase from CNY 43,609,447.92 in the previous year[54] - The net cash flow from financing activities was CNY 1,616,608.43, a decrease from CNY 155,472,762.26 in the same period last year[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,680,943,536.95, a slight increase of 0.19% from ¥4,672,225,564.65 at the end of the previous year[7] - The company's current assets decreased to CNY 2,058,029,299.04 from CNY 2,083,031,416.41, primarily due to a reduction in cash and cash equivalents[36][37] - The total liabilities decreased to CNY 1,370,489,495.51 from CNY 1,409,302,025.06, indicating improved financial stability[38][39] - The company's equity attributable to shareholders increased to CNY 3,016,146,437.13 from CNY 2,978,092,925.07, reflecting a growth of approximately 1.9%[39] Shareholder Information - The company reported a total of 24,451 common shareholders at the end of the reporting period[10] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 30.97% of the shares, amounting to 151,767,378 shares[10] Investment and Projects - The investment in the Inner Mongolia Yiduoli enzyme preparation project reached 99.80% completion with an investment of 9,480.7 million[25] - The marketing service network construction project has utilized 1,944.9 million, achieving 77.80% of its planned investment[25] - The acquisition of Hunan Hongying Biotechnology Co., Ltd. was completed with a cash consideration of 5,650 million, achieving 100% completion[26] - The company plans to adjust the investment of 1 billion CNY (100 million) from the original "annual production of 20,000 tons of biological enzyme preparation project" to the "annual production of 1,200 tons of steroid drugs and intermediates project"[27] Financial Management - The company has no violations regarding external guarantees during the reporting period[30] - There are no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[31] - The company reported a significant reduction in short-term borrowings, which decreased to CNY 570,762,500.00 from CNY 635,884,185.00, a decline of approximately 10.2%[38] Research and Development - Research and development expenses increased to CNY 26,180,795.15 from CNY 20,884,099.44, highlighting a focus on innovation[45] Miscellaneous - The company did not engage in any repurchase transactions during the reporting period[11] - The company did not undergo an audit for the first quarter report[60] - The report indicates that the new leasing standards were not applicable for the current period[59]